FIELD: immunology, biotechnology.
SUBSTANCE: invention describes murine antibody and its humanized variant (CDP870) showing specificity to human tumor necrosis factor-alpha. Amino acid sequence is given in the description. Also, invention describes compounds showing affinity with respect to human tumor necrosis factor-alpha based on humanized antibody wherein lysylmaleimide group bound covalently with one or some methoxypoly(ethylene glycol) molecules by lysyl residue is joined to one of cysteine residues by C-end of heavy chain of the humanized antibody. Invention discloses DNA sequences encoding antibodies showing specificity to human tumor necrosis factor-alpha and variants if expression vectors involving indicated DNAs. Also, invention describes variants of a method for preparing a host-cell using expression vectors and variants of a method for preparing antibodies based on prepared host-cells. Invention discloses therapeutic compositions used in treatment of pathology mediated by tumor necrosis factor-alpha based on antibodies. Invention provides providing antibodies showing high affinity: 0.85 x 10-10 M for murine antibodies and 0.5 x 10-10 M for its humanized variant and low immunogenicity for human for humanized antibodies. Part of patients with improved ACR20 in administration of 5 and 20 mg/kg of CDP870 is 75% and 75% in 8 weeks, respectively. Half-life value of CDP870 in plasma is 14 days.
EFFECT: valuable biological and medicinal properties of antibodies.
58 cl, 24 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO HUMAN CD22, AND THEIR USES IN THERAPY AND DIAGNOSTICS | 2003 |
|
RU2342401C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2567100C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2018 |
|
RU2678120C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2653753C1 |
| ISOLATED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, ISOLATED NUCLEIC ACID (VARIANTS), RECOMBINANT EXPRESSION VECTOR, USING HOST-CELLS FOR EXPRESSION OF ANTIBODY AND METHOD FOR ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF ACTIVITY OF HUMAN TNFα | 1997 |
|
RU2268266C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFΑ | 2018 |
|
RU2704838C1 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNF ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT | 1997 |
|
RU2270030C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
